Altimmune Stock Price, News & Analysis

Altimmune, Inc. (Nasdaq: ALT) announced plans to report its fourth quarter and full year 2022 financial results on February 28, 2023. The company will also provide a business update during the conference call scheduled for 8:30 AM ET that day. The call will be accessible via their Investor Relations website. Altimmune focuses on developing novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), targeting obesity and NASH. Additionally, the company is working on HepTcell™, aimed at chronic hepatitis B treatment.

Altimmune, Inc. has appointed Raymond Jordt as the new Chief Business Officer, effective January 1, 2023. He succeeds José Ochoa, who is leaving for other opportunities. Jordt brings over 25 years of pharmaceutical experience, most recently with Eli Lilly, where he held various roles, including Head of Transactions. Under his leadership, significant portfolio transformations occurred. CEO Vipin Garg expressed optimism about Jordt's expertise aiding the clinical development of the company's key candidates, pemvidutide and HepTcell, targeting obesity, NASH, and hepatitis B.

Altimmune, Inc. announced that Dr. Stephen A. Harrison will present results from the 12-week Phase 1b and subsequent extension trials of pemvidutide for non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference on January 7, 2023. Pemvidutide, a dual receptor agonist for obesity and NASH, showed significant reductions in liver fat and body weight. The company is focused on the development of innovative therapeutic solutions targeting liver diseases and obesity, with pemvidutide being a key candidate.

Altimmune has reported positive topline results from a 24-week trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). At doses of 1.8 mg and 2.4 mg, participants achieved significant reductions in liver fat content, with over 75% relative decrease observed. The trial also reported notable declines in serum alanine aminotransferase and improved glycemic control. Weight loss averages reached 7.2% for non-diabetic subjects. Pemvidutide showed a favorable safety profile, with mostly mild adverse events. The results suggest potential for advancement to Phase 2b trials for NAFLD.

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), will participate in two upcoming investor conferences. The first is the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, featuring a fireside chat at 10:55 am ET. The second is the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, with a fireside chat at 10:00 am ET. Both sessions will be accessible via webcast on Altimmune's website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with notable products like pemvidutide (ALT-801).

Altimmune, Inc. (Nasdaq: ALT) reported its financial results for Q3 2022, revealing a net loss of $23.5 million, or $0.48 per share, an improvement from a $33.5 million loss in Q3 2021. The company holds $201.9 million in cash and equivalents as of September 30, 2022. Key upcoming milestones include topline data from a 24-week Phase 1b NAFLD trial expected in mid-December 2022 and interim results from the MOMENTUM Phase 2 obesity trial anticipated in Q1 2023. The company aims to leverage significant reductions in liver fat and body weight from its pemvidutide program.

Altimmune, Inc. (Nasdaq: ALT) will report its Q3 2022 financial results on November 10, 2022, followed by a management conference call at 8:30 am ET. The discussion will focus on financial performance and business updates. Live streaming of the call will be available on the company's Investor Relations website. Altimmune specializes in peptide-based therapeutics for obesity and liver diseases, with its lead candidate being pemvidutide, aimed at treating obesity and non-alcoholic steatohepatitis (NASH).

Altimmune, Inc. (Nasdaq: ALT) announced its upcoming scientific presentations at two conferences in November 2022. The first presentation, at the American Heart Association Scientific Sessions on November 5, will focus on the effects of Pemvidutide (ALT-801) on lipid mediators. The second, at the American Association for the Study of Liver Disease on November 7, will present results from a Phase 1b trial evaluating a dual receptor agonist's impact on liver fat reduction in patients with non-alcoholic fatty liver disease. Presentation materials will be accessible on Altimmune's website.

Altimmune, Inc. (Nasdaq: ALT) announced the successful completion of patient dosing for its Phase 2 MOMENTUM trial, evaluating the efficacy and safety of pemvidutide, a dual receptor agonist for obesity and NASH. This multicenter trial involves 320 subjects randomized to receive various doses of pemvidutide or placebo over 48 weeks, focusing on weight change and metabolic profiles. The trial's 24-week interim analysis is anticipated in Q1 2023, marking a significant milestone in pemvidutide's development.